Retatrutide vs PT-141
A comprehensive, data-driven comparison of Retatrutide (LY3437943) and PT-141 (Bremelanotide). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | Retatrutide LY3437943 | PT-141 Bremelanotide, Vyleesi |
|---|---|---|
| FDA Status | Phase 3 (NDA expected late 2026) | FDA Approved |
| Category | Weight Loss | Sexual Health |
| Primary Use | Obesity and weight management | Hypoactive sexual desire disorder (HSDD) in women |
| Weight Loss % | 28.7% | N/A |
| Monthly Cost | $1,200 - $1,500/mo | $800 - $1,200/mo |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Dose | 12mg weekly (dose escalated from 2mg) | 1.75mg as needed, at least 45 min before activity |
| Frequency | Weekly | As needed |
| Mechanism | Triple agonist targeting GIP, GLP-1, and glucagon receptors to enhance insulin secretion, reduce appetite, and increase energy expenditure | Melanocortin receptor agonist that activates central nervous system pathways involved in sexual arousal |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | High | High |
| Clinical Trial Phase | Phase 3 | Approved |
Key Differences
- 1PT-141 is FDA-approved, while Retatrutide is currently phase 3 (nda expected late 2026).
- 2Retatrutide has clinical weight loss data (28.7%), while PT-141 is not primarily indicated for weight loss.
- 3PT-141 is generally more affordable ($800 - $1,200/mo) compared to Retatrutide ($1,200 - $1,500/mo).
- 4Retatrutide is dosed weekly, while PT-141 is as needed.
- 5They belong to different categories: Retatrutide (Weight Loss) vs PT-141 (Sexual Health).
Which Is Better For...
PT-141
Those seeking an FDA-approved treatment with established safety data
PT-141
More budget-friendly option with lower monthly costs
PT-141
More convenient dosing schedule (as needed)
PT-141
Fewer commonly reported side effects
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| Retatrutide | $1,200 - $1,500/mo | Phase 3 (NDA expected late 2026) | Eli Lilly |
| PT-141 | $800 - $1,200/mo | FDA Approved | Cosette Pharmaceuticals (Covis Pharma) |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
Retatrutide works via Triple agonist targeting GIP, GLP-1, and glucagon receptors to enhance insulin secretion,. PT-141 works via Melanocortin receptor agonist that activates central nervous system pathways involved in sexual. They differ in FDA approval status, efficacy data, and cost.
Retatrutide has demonstrated 28.7% average weight loss in clinical trials. PT-141 is not primarily used for weight loss.
Retatrutide typically costs $1,200 - $1,500/mo, while PT-141 costs $800 - $1,200/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
Retatrutide is not FDA-approved (Phase 3 (NDA expected late 2026)). PT-141 is FDA-approved. FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of Retatrutide include Nausea, Diarrhea, Vomiting. Common side effects of PT-141 include Nausea, Flushing, Injection site reactions. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
Retatrutide is a novel triple-receptor agonist developed by Eli Lilly currently in Phase 3 clinical trials. It has demonstrated unprecedented weight loss results, with patients losing an average of 28...
View Full Retatrutide GuidePT-141 (Bremelanotide) is an FDA-approved peptide medication marketed as Vyleesi for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors like Viagra, PT-14...
View Full PT-141 GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between Retatrutide and PT-141 should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.